ES8600239A1 - Un procedimiento para preparar 4-aminoalquil-2(3h)-indolonas - Google Patents

Un procedimiento para preparar 4-aminoalquil-2(3h)-indolonas

Info

Publication number
ES8600239A1
ES8600239A1 ES527827A ES527827A ES8600239A1 ES 8600239 A1 ES8600239 A1 ES 8600239A1 ES 527827 A ES527827 A ES 527827A ES 527827 A ES527827 A ES 527827A ES 8600239 A1 ES8600239 A1 ES 8600239A1
Authority
ES
Spain
Prior art keywords
indolones
aminoalkyl
series
propylaminoethyl
indolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES527827A
Other languages
English (en)
Other versions
ES527827A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23776840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8600239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of ES8600239A1 publication Critical patent/ES8600239A1/es
Publication of ES527827A0 publication Critical patent/ES527827A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR 4-AMINOALQUIL-2(3H)-INDOLONAS.COMPRENDE CICLIZAR EN CONDICIONES REDUCTORAS UN COMPUESTO DE FORMULA (II) PARA OBTENER 4-AMINOALQUIL-2(3H)-INDOLONAS DE FORMULA (I) DONDE CADA R ES H, ALQUILO INFERIOR C 1 A 6, BENCILO, ALILO Y OTROS; Y R1, R2 Y R3 SON, CADA UNO, H O ALQUILO INFERIOR C 1 A 4. LA REACCION SE LLEVA A CABO EN PRESENCIA DE UN DISOLVENTE, TAL COMO ACETONA ACUOSA, DIMETILFORMAMIDA O DIMETILACETAMIDA, DURANTE UN TIEMPO DE UNO A DOS DIAS Y A UNA TEMPERATURA ELEVADA, COMO HASTA 75JC.TIENE UTILIDAD COMO AGONISTAS DE LA DOPAMINA PARA EL TRATAMIENTO DE LOS TRASTORNOS DEL SISTEMA CARDIOVASCULAR, DE LA HIPERTENSION, DE LA ANGINA DE PECHO Y PARA TRATAR LOS SINTOMAS DE LA INSUFICIENCIA CARDIACA CONGESTIVA O PARA MEJORAR LA FUNCION DEL RIN/ON.
ES527827A 1982-12-07 1983-12-06 Un procedimiento para preparar 4-aminoalquil-2(3h)-indolonas Granted ES527827A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/447,564 US4452808A (en) 1982-12-07 1982-12-07 4-Aminoalkyl-2(3H)-indolones

Publications (2)

Publication Number Publication Date
ES8600239A1 true ES8600239A1 (es) 1985-10-01
ES527827A0 ES527827A0 (es) 1985-10-01

Family

ID=23776840

Family Applications (2)

Application Number Title Priority Date Filing Date
ES527827A Granted ES527827A0 (es) 1982-12-07 1983-12-06 Un procedimiento para preparar 4-aminoalquil-2(3h)-indolonas
ES543593A Expired ES8604143A1 (es) 1982-12-07 1985-05-29 Un procedimiento para preparar 4-aminoalquil-2(3h)-indolonas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES543593A Expired ES8604143A1 (es) 1982-12-07 1985-05-29 Un procedimiento para preparar 4-aminoalquil-2(3h)-indolonas

Country Status (27)

Country Link
US (1) US4452808A (es)
EP (1) EP0113964B1 (es)
JP (1) JPS59112964A (es)
KR (1) KR910001042B1 (es)
AU (1) AU560170B2 (es)
BR (1) BR1100036A (es)
CA (1) CA1208650A (es)
CY (1) CY1497A (es)
CZ (1) CZ398191A3 (es)
DE (1) DE3367090D1 (es)
DK (1) DK156514C (es)
DZ (1) DZ587A1 (es)
EG (1) EG16556A (es)
ES (2) ES527827A0 (es)
FI (1) FI77849C (es)
GR (1) GR79121B (es)
HK (1) HK82089A (es)
IE (1) IE56347B1 (es)
IL (1) IL70311A (es)
LU (1) LU90097I2 (es)
NL (1) NL970005I2 (es)
NO (2) NO160135C (es)
NZ (1) NZ206344A (es)
PH (1) PH22067A (es)
PT (1) PT77739B (es)
ZA (1) ZA839094B (es)
ZW (1) ZW25883A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588740A (en) * 1982-12-07 1986-05-13 Smithkline Beckman Corporation Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones
US4657929A (en) * 1983-10-25 1987-04-14 Fisons Plc Compounds
US4554284A (en) * 1984-09-12 1985-11-19 Smithkline Beckman Corporation 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
GB8621040D0 (en) * 1986-08-30 1986-10-08 Smith Kline French Lab Process
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
GB9015095D0 (en) * 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
AU4312593A (en) * 1992-05-18 1993-12-13 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
GB9300309D0 (en) * 1993-01-08 1993-03-03 Smithkline Beecham Plc Process
TW356468B (en) * 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
GB9526511D0 (en) * 1995-12-23 1996-02-28 Astra Pharma Prod Pharmaceutically active compounds
EP0923551B1 (en) * 1996-08-27 2002-06-05 American Home Products Corporation 4-aminoethoxy indolone derivatives
AU3555099A (en) * 1998-04-13 1999-11-01 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
FR2821843B1 (fr) * 2001-03-12 2003-05-09 Servier Lab Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
ATE358488T1 (de) * 2002-09-13 2007-04-15 Motac Neuroscience Ltd Behandlung von dyskinesie mit 2,3-benzodiazepinen
AU2003267557B2 (en) * 2002-09-17 2009-02-26 Motac Neuroscience Limited Treatment of dyskinesia
ES2237307B1 (es) * 2003-10-14 2006-11-01 Urquima, S.A. Procedimiento para la preparacion de ropinirol.
WO2005074387A2 (en) * 2003-12-30 2005-08-18 Sun Pharmaceutical Industries Limited Novel crystal forms of 4-[2-di-n-propylamino)ethyl]-2 (3h)- indolone hydrochloride
US7378439B2 (en) * 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
WO2005105741A1 (en) * 2004-02-11 2005-11-10 Sun Pharmaceutical Industries Limited Substantially pure 4-[2-(di-n-propylamino)ethyl]-2(3h)-indolone hydrochloride
WO2005080333A1 (en) * 2004-02-19 2005-09-01 Torrent Pharmaceuticals Ltd Process for purification of ropinirole
PL1751106T3 (pl) * 2004-05-11 2009-07-31 Egis Gyogyszergyar Nyrt Piperazynowe pochodne alkilooksyindoli
HUP0400953A3 (en) * 2004-05-11 2008-02-28 Egis Gyogyszergyar Nyilvanosan Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
EP1863484A1 (en) * 2005-03-21 2007-12-12 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CN100457711C (zh) * 2005-06-27 2009-02-04 上海奥博生物医药技术有限公司 2-甲基-3-硝基苯基烷基胺衍生物或其盐的制备方法
WO2007010557A2 (en) * 2005-07-22 2007-01-25 Ind-Swift Laboratorie Limted Process for the preparation of highly pure ropinirole
US7968731B2 (en) 2006-03-29 2011-06-28 Alembic Limited Process for the purification of Ropinirole hydrochloride
EA017896B1 (ru) 2006-04-06 2013-04-30 Нюпэф Инк. Имплантаты для лечения состояний, ассоциируемых с допамином
US20070254941A1 (en) * 2006-04-21 2007-11-01 Glenmark Pharmaceuticals Limited Subtantially pure ropinirole hydrochloride, polymorphic form of ropinirole and process for their preparation
CN100457732C (zh) * 2006-05-25 2009-02-04 药源药物化学（上海）有限公司 罗匹尼罗的制备方法
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
ATE535243T1 (de) * 2007-05-11 2011-12-15 Santen Pharmaceutical Co Ltd Prophylaktisches oder therapeutisches mittel für posteriore augenerkrankung mit selektivem nicht- ergot-d2-rezeptoragonist als wirkstoff
US20090076124A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched ropinirole
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
WO2010023693A2 (en) * 2008-09-01 2010-03-04 Lupin Limited Novel controlled release compositions of ropinirole
EP2452677A1 (en) 2008-09-29 2012-05-16 Wockhardt Limited Extended release dosage form of ropinirole
WO2010060070A2 (en) * 2008-11-24 2010-05-27 Auspex Pharmaceuticals, Inc. Indolinone modulators of dopamine receptor
EP2438917B1 (en) 2009-05-21 2014-09-03 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation
WO2011072704A1 (en) * 2009-12-16 2011-06-23 Pharmathen S.A. Process for the preparation of ropinirole and salts thereof
MY153762A (en) 2010-04-30 2015-03-13 Teikoku Pharma Usa Inc Propynylaminoindan transdermal compositions
CN101891641B (zh) * 2010-07-27 2015-06-10 北京华禧联合科技发展有限公司 盐酸罗匹尼罗关键中间体的稳定形态及其制备
TWI537274B (zh) 2011-03-14 2016-06-11 橘生藥品工業股份有限公司 新穎之八氫噻吩并喹啉衍生物、含有其之醫藥組成物及該等之用途
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
BR112015007872A2 (pt) 2012-11-02 2017-07-04 Teikoku Pharma Usa Inc composições transdermais de propinilaminoindano
WO2014092006A1 (ja) 2012-12-10 2014-06-19 キッセイ薬品工業株式会社 新規なオクタヒドロピリドキナゾリン誘導体、それを含有する医薬組成物およびそれらの用途
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
WO2018227553A1 (zh) 2017-06-16 2018-12-20 浙江华海立诚药业有限公司 盐酸罗匹尼罗的纯化方法
CN115466209A (zh) * 2022-09-29 2022-12-13 南通大学 一种罗匹尼罗环戊烷并吲哚酮杂质的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA895875A (en) * 1972-03-21 Bourdais Jacques Mercapto indole derivatives
US3573310A (en) * 1967-09-28 1971-03-30 Miles Lab 1-substituted derivatives of 2-indolinone
JPS5825673B2 (ja) * 1976-03-31 1983-05-28 大塚製薬株式会社 オキシインド−ル誘導体
JPS5840539B2 (ja) * 1976-03-31 1983-09-06 大塚製薬株式会社 α−置換アミノアルカノイルオキシインド−ル誘導体
JPS5919537B2 (ja) * 1976-08-02 1984-05-07 大塚製薬株式会社 オキシインド−ル誘導体
US4317944A (en) * 1980-08-15 1982-03-02 General Electric Company Preparation of 2,2-bis(4-hydroxyphenyl) propane
US4314944A (en) * 1980-08-22 1982-02-09 Smithkline Corporation 4-Aminoalkyl-7-hydroxy-2(3H)-indolones

Also Published As

Publication number Publication date
IE56347B1 (en) 1991-07-03
AU2158583A (en) 1984-06-14
NO1999011I1 (no) 1999-06-18
NL970005I2 (nl) 1997-10-01
CA1208650A (en) 1986-07-29
GR79121B (es) 1984-10-02
ZW25883A1 (en) 1984-04-18
DE3367090D1 (de) 1986-11-27
LU90097I2 (fr) 1997-07-16
FI77849C (fi) 1989-05-10
JPS59112964A (ja) 1984-06-29
FI834421A (fi) 1984-06-08
CZ398191A3 (en) 1993-02-17
DZ587A1 (fr) 2004-09-13
DK562183A (da) 1984-06-08
NO160135B (no) 1988-12-05
JPH0150703B2 (es) 1989-10-31
DK562183D0 (da) 1983-12-06
IE832866L (en) 1984-06-07
IL70311A0 (en) 1984-02-29
FI834421A0 (fi) 1983-12-02
NO160135C (no) 1989-03-15
EP0113964A1 (en) 1984-07-25
DK156514B (da) 1989-09-04
EG16556A (en) 1989-01-30
ES8604143A1 (es) 1986-01-16
NZ206344A (en) 1987-03-31
ES543593A0 (es) 1986-01-16
PT77739A (en) 1983-12-01
NO834485L (no) 1984-06-08
PH22067A (en) 1988-05-20
BR1100036A (pt) 2000-01-11
HK82089A (en) 1989-10-20
PT77739B (en) 1986-03-27
NL970005I1 (nl) 1997-04-01
AU560170B2 (en) 1987-04-02
US4452808A (en) 1984-06-05
ES527827A0 (es) 1985-10-01
IL70311A (en) 1986-11-30
FI77849B (fi) 1989-01-31
CY1497A (en) 1990-02-16
KR910001042B1 (ko) 1991-02-21
EP0113964B1 (en) 1986-10-22
KR840006963A (ko) 1984-12-04
DK156514C (da) 1990-03-12
ZA839094B (en) 1985-02-27

Similar Documents

Publication Publication Date Title
ES8600239A1 (es) Un procedimiento para preparar 4-aminoalquil-2(3h)-indolonas
YU116978A (en) Process for obtainig the dextro-isomer of the asymmetric spirohydantoin compound
DE3369115D1 (en) Process for dewatering sludge
ES8300758A1 (es) Un procedimiento para la preparacion de nuevos pirazimil-1,2,4 oxadiazol-5-onas.
IL69146A (en) Process for preparation of epimers of 1-oxa-dethiacephem compounds
DE3166485D1 (en) Process for the production of calcium carbide
YU166685A (en) Process for executing chemical reaction of dehydratation
GB2096169B (en) Production of chemical compounds from viable cells
JO1213B1 (en) Industrial sewage treatment unit
YU166380A (en) Process for the chemical elimination of phosphoric compounds from waste water
YU42428B (en) PROCESS FOR CONVERSION OF 1,1-DIOXIDE-2-METOXIETHYL-4-HYDROXI-2-METHYL-2h-1,2-BENZOTHIAZIN-3-CARBOXILATE
AU559542B2 (en) A process to increase the effectiveness of bagasse as a source of energy
AU570921B2 (en) Phosphohemihydrate process for purification of gypsum
PT77426B (en) Process for the production of 7-substituted-3-vinyl-3-cephem compounds
DE3062562D1 (en) Process for purifying waste water with a high concentration of nitrogen compounds
JPS5219470A (en) Method of treating waste water containing fluorborate compound
PT77832A (en) Plant for the production of calcium carbide
ZA832578B (en) Process for the operation of the gypsum-sulfuric acid plant
MY101988A (en) 4-aminoalkyl-2<3h>-indolones
IL47073A (en) Process for the purification of waste waters containing heavy metal compounds
ES8302724A1 (es) Procedimiento de preparacion de alcoxiaminohidridosilanos.
GB2022068B (en) Formation of cyanate compounds
ZA816425B (en) Process for the dewatering of sludge
SU1089799A1 (ru) Способ очистки газов от сернистых соединений
JPS51119380A (en) A method for removing hydrogen chloride from waste gas

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20050611